Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus SOMA.
LIORESAL vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Clinical Note
moderateSomatostatin + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin."
Clinical Note
moderateSomatostatin + Methylphenobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital."
Clinical Note
moderateSomatostatin + Hexobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital."
Clinical Note
moderate1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Somatostatin + Thiamylal
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal."